BrainsWay Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRSYF research report →
Companywww.brainsway.com
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
- CEO
- Hadar Levy
- IPO
- 2011
- Employees
- 120
- HQ
- Jerusalem, IL
Price Chart
Valuation
- Market Cap
- $674.29M
- P/E
- 76.07
- P/S
- 10.77
- P/B
- 7.93
- EV/EBITDA
- 86.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.42%
- Op Margin
- 8.28%
- Net Margin
- 13.50%
- ROE
- 11.10%
- ROIC
- 5.05%
Growth & Income
- Revenue
- $56.53M · 37.83%
- Net Income
- $8.26M · 182.87%
- EPS
- $0.22 · 155.81%
- Op Income
- $4.68M
- FCF YoY
- 170.83%
Performance & Tape
- 52W High
- $16.84
- 52W Low
- $3.40
- 50D MA
- $13.60
- 200D MA
- $9.41
- Beta
- 0.22
- Avg Volume
- 18
Get TickerSpark's AI analysis on BRSYF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BRSYF Coverage
We haven't published any research on BRSYF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BRSYF Report →